Related Experiment Video
Updated: Jun 6, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
CyberKnife stereotactic ablative radiotherapy for lung tumors
1Department of Radiation Oncology Stanford University and Cancer Center 875 Blake Wilbur Drive, MC 5847 Stanford, CA 94305-5847, USA. iris.gibbs@stanford.edu
Technology in Cancer Research & Treatment
|November 13, 2010
Summary
Stereotactic ablative radiotherapy (SABR) offers effective treatment for early-stage non-small cell lung cancer. The CyberKnife system demonstrates high local tumor control rates for lung tumors, even those moving with respiration.
Area of Science:
- Oncology
- Radiotherapy
- Medical Physics
Background:
- Stereotactic ablative radiotherapy (SABR) is a key treatment for early-stage non-small cell lung cancer (NSCLC).
- SABR is suitable for patients who cannot undergo surgery.
- It offers high local tumor control with manageable toxicity and a short treatment duration.
Purpose of the Study:
- To review the suitability of the CyberKnife system for lung tumor SABR.
- To summarize clinical data on CyberKnife for lung tumor SABR.
Main Methods:
- Review of CyberKnife platform features relevant to lung tumor SABR.
- Summary of published clinical outcomes for lung tumor SABR using CyberKnife.
Main Results:
- CyberKnife's image-guidance and robotic precision are advantageous for lung tumors affected by respiratory motion.
- Clinical data indicate high rates of local tumor control with acceptable toxicity.
Conclusions:
- The CyberKnife system is well-suited for performing SABR on lung tumors.
- CyberKnife facilitates effective and safe SABR for early-stage NSCLC, especially in patients unsuitable for surgery.
